Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 67 full-time employees. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Follow-Up Questions
Who is the CEO of Abivax SA?
Mr. Marc De Garidel is the Chief Executive Officer of Abivax SA, joining the firm since 2023.
What is the price performance of ABVX stock?
The current price of ABVX is $81.98, it has decreased 1.59% in the last trading day.
What are the primary business themes or industries for Abivax SA?
Abivax SA belongs to Biotechnology industry and the sector is Health Care
What is Abivax SA market cap?
Abivax SA's current market cap is $6.1B
Is Abivax SA a buy, sell, or hold?
According to wall street analysts, 7 analysts have made analyst ratings for Abivax SA, including 6 strong buy, 6 buy, 1 hold, 0 sell, and 6 strong sell
